Nanoparticle derivatives of gemcitabine
AssigneesCentre National de la Recherche Scientifique (CNRS), Universite Paris-Sud
InventorsPatrick Couvreur, Barbara Stella, Luigi Cattel, Flavio Rocco, Jack-Michel Renoir, Veronique Rosilio
Life of this patent
Estimating the term…
Abstract
The use of squalenic acid or a derivative thereof in formulating at least one polar active principle with a molecular weight of 100 Da or more, in the form of nanoparticles, and pharmaceutical compositions thereof.
Claims14
A process for preparing nanoparticles of at least one active principle with polar nature and with a molecular weight of more than 100 Da, comprising:
- covalently coupling at least one molecule of squalenic acid or a derivative thereof with said at least one active principle with polar nature and with a molecular weight of more than 100 Da wherein said nanoparticles are formed.
A nanoparticle comprising:
- at least one active principle with polar nature covalently coupled to at least one molecule of squalenic acid or a derivative thereof, wherein said nanoparticle has a molecular weight of more than 100 Da.
A pharmaceutical composition, comprising:
- nanoparticles of at least one active principle with polar nature covalently coupled with squalenic acid or a derivative thereof and with a molecular weight of more than 100 Da;
- and
- at least one pharmaceutically acceptable vehicle.
A process for preparing a pharmaceutical composition comprising, as an active material, at least one active principle with polar nature and with a molecular weight of more than 100 Da or nanoparticles thereof, said process comprising at least the step of formulating said at least one active principle with polar nature and with a molecular weight of more than 100 Da with squalenic acid or a derivative thereof wherein nanoparticles are formed.
Dependencies are inferred from the claim text.